Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age

Yen-Chih Chen, San-Ni Chen, Benjamin Chi-Lan Yang, Kun-Hsien Lee, Chih-Chun Chuang, Chieh-Yin Cheng, Yen-Chih Chen, San-Ni Chen, Benjamin Chi-Lan Yang, Kun-Hsien Lee, Chih-Chun Chuang, Chieh-Yin Cheng

Abstract

Purpose: To compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab (IVR) versus bevacizumab (IVB), at a corrected age of 3 years.

Methods: A retrospective case series compared cycloplegic refractive statuses and biometric statuses in patients who received either IVR or IVB for type 1 ROP, from April 2011 to April 2014.

Results: A total of 62 eyes (33 patients) with type 1 ROP were evaluated (26 eyes in 13 IVR patients and 36 eyes in 20 IVB patients). There were no differences in birth statuses including gestational age and birth body weight between the two groups. The prevalence of refractive error greater than 1 D was higher in the IVB group (p = 0.03), and there was a higher prevalence of high myopia (<-5.0 D, p = 0.03) in the IVB group. Comparisons in biometric finding showed that IVB patients had shallower anterior chamber depth (p = 0.01).

Conclusion: Both IVR and IVB showed low refractive errors, even followed at the corrected age of 3 years. No difference was noted between the two groups in refractive statuses. However, IVB was associated with shallower anterior chamber and higher prevalence of refractive error at the corrected age of 3 years. This trial is registered with NCT03334513.

Figures

Figure 1
Figure 1
Box plots showing the distribution of refractive status and biometric comparisons at the corrected age of 3 years in children with ROP, treated with IVIs of either ranibizumab or bevacizumab. (a) Spherical equivalent; (b) astigmatism; (c) axial length; (d) anterior chamber depth; (e) cornea radius; (f) lens thickness. There was a significant difference only in anterior chamber depth (p = 0.01) between the eyes in the two groups but the differences were not seen in other parameters.

References

    1. Good W. V., Early treatment for retinopathy of prematurity cooperative group Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Transactions of the American Ophthalmological Society. 2004;102:233–248.
    1. Axer-Siegel R., Maharshak I., Snir M., et al. Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes. Retina. 2008;28(6):839–846. doi: 10.1097/IAE.0b013e318169faee.
    1. Dhawan A., Dogra M., Vinekar A., Gupta A., Dutta S. Structural sequelae and refractive outcome after successful laser treatment for threshold retinopathy of prematurity. Journal of Pediatric Ophthalmology and Strabismus. 2008;45(6):356–361. doi: 10.3928/01913913-20081101-02.
    1. Sahni J., Subhedar N. V., Clark D. Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomical outcomes at 6 months and 36 months. The British Journal of Ophthalmology. 2005;89(2):154–159. doi: 10.1136/bjo.2004.045815.
    1. Mintz-Hittner H. A., Kennedy K. A., Chuang A. Z., BEAT-ROP Cooperative Group Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. The New England Journal of Medicine. 2011;364(7):603–615. doi: 10.1056/NEJMoa1007374.
    1. Wu W. C., Yeh P. T., Chen S. N., Yang C. M., Lai C. C., Kuo H. K. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology. 2011;118(1):176–183. doi: 10.1016/j.ophtha.2010.04.018.
    1. Wu W. C., Kuo H. K., Yeh P. T., Yang C. M., Lai C. C., Chen S. N. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. American Journal of Ophthalmology. 2013;155(1):150–158.e1. doi: 10.1016/j.ajo.2012.06.010.
    1. Harder B. C., Schlichtenbrede F. C., von Baltz S., Jendritza W., Jendritza B., Jonas J. B. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. American Journal of Ophthalmology. 2013;155(6):1119–1124.e1. doi: 10.1016/j.ajo.2013.01.014.
    1. Hwang C. K., Hubbard G. B., Hutchinson A. K., Lambert S. R. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122(5):1008–1015. doi: 10.1016/j.ophtha.2014.12.017.
    1. Zhang G., Yang M., Zeng J., et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina. 2017;37(4):710–717. doi: 10.1097/IAE.0000000000001241.
    1. Wu W. C., Shih C. P., Lien R., et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina. 2017;37(4):694–701. doi: 10.1097/IAE.0000000000001209.
    1. Chan J. J. T., Lam C. P. S., Kwok M. K. M., et al. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy. Scientific Reports. 2016;6(1, article 27082) doi: 10.1038/srep27082.
    1. Chuluunbat T., Paul Chan R. V., Wang N.-K., et al. Nonresponse and recurrence of retinopathy of prematurity after intravitreal ranibizumab treatment. Ophthalmic Surgery, Lasers and Imaging Retina. 2016;47(12):1095–1105. doi: 10.3928/23258160-20161130-03.
    1. Erol M. K., Coban D. T., Sari E. S., et al. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arquivos Brasileiros de Oftalmologia. 2015;78(6):340–343. doi: 10.5935/0004-2749.20150090.
    1. Chen S. N., Lian I., Hwang Y. C., et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab. Retina. 2015;35(4):667–674. doi: 10.1097/IAE.0000000000000380.
    1. Chen T. C., Tsai T. H., Shih Y. F., et al. Long-term evaluation of refractive status and optical components in eyes of children born prematurely. Investigative Ophthalmology & Visual Science. 2010;51(12):p. 6140. doi: 10.1167/iovs.10-5234.
    1. Wu W. C., Lin R. I., Shih C. P., et al. Visual acuity, optical components, and macular abnormalities in patients with a history of retinopathy of prematurity. Ophthalmology. 2012;119(9):1907–1916. doi: 10.1016/j.ophtha.2012.02.040.
    1. Smith E. L., III Prentice Award Lecture 2010: a case for peripheral optical treatment strategies for myopia. Optometry and Vision Science. 2011;88(9):1029–1044. doi: 10.1097/OPX.0b013e3182279cfa.
    1. Robinson G. S., Ju M., Shih S. C., et al. Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. The FASEB Journal. 2001;15(7):1215–1217. doi: 10.1096/fj.00-0598fje.
    1. Wang J., Ren X., Shen L., Yanni S. E., Leffler J. N., Birch E. E. Development of refractive error in individual children with regressed retinopathy of prematurity. Investigative Opthalmology & Visual Science. 2013;54(9):6018–6024. doi: 10.1167/iovs.13-11765.
    1. Yang C. S., Wang A. G., Shih Y. F., Hsu W. M. Long-term biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age. Acta Ophthalmologica. 2013;91(4):e276–e282. doi: 10.1111/aos.12053.
    1. Connolly B. P., Ng E. Y. J., Arch McNamara J., Regillo C. D., Vander J. F., Tasman W. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years. Ophthalmology. 2002;109(5):936–941. doi: 10.1016/S0161-6420(01)01015-6.
    1. Fielder A. R., Quinn G. E. Myopia of prematurity: nature, nurture, or disease? The British Journal of Ophthalmology. 1997;81(1):2–3. doi: 10.1136/bjo.81.1.2.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir